The R&D World Index (RDWI) for the week ending March 7, 2025, closed at 4,106.42 for the 25 companies in the RDWI. The Index dipped –1.37% (or -56.96 basis points). Seventeen RDWI members gained value last week from 0.08% (Stellantis NV) to 12.51% (Volkswagen AG). Eight RDWI members lost value the previous week from -0.25%…
7 major R&D moves this week: Apple expands U.S. manufacturing, Lilly plans new plants, tech giants advance in computing
The R&D World Index saw a slight gain of 0.22% last week, closing at 4,163.38 points. Corporate actions focused heavily on new manufacturing investments, with Apple doubling its Advanced Manufacturing Fund and Eli Lilly announcing plans for four new U.S. drug manufacturing plants. Technology companies continued their push in advanced computing, with Amazon and Google…
7 major R&D moves this week: Lilly and Merck launch a consortium with Purdue, Continental to cut jobs, Apple latest phone and more
The R&D World Index saw a slight gain last week amidst a landscape of innovation and cost-cutting within global industries. Pharma giants Eli Lilly and Merck announced a partnership with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium, aimed at bolstering domestic pharmaceutical production. However, automotive supplier Continental AG revealed further job cuts…
7 major R&D moves this week: Honda and Nissan end merger talks, Baidu to launch driver-less taxis in UAE, Chevron is moving
The R&D World Index saw gains this week, driven partly by a surge in Intel’s value amid significant developments across various sectors. Honda and Nissan have ended their merger talks, citing concerns over autonomy and decision-making, while GlaxoSmithKline consolidates its vaccine R&D in Cambridge, MA. Novartis is set to reacquire rights to a blood clot…
Ericsson launches Cognitive Labs to advance AI research in telecom, healthcare
Ericsson has introduced Cognitive Labs, a virtual research initiative dedicated to advancing artificial intelligence (AI) technologies such as Graph Neural Networks (GNNs), Active Learning, and Large-Scale Language Models (LLMs). The program operates with teams in Madrid, Málaga, and Cairo. Focus areas include enhancing mobile communications and exploring emerging technology applications in sectors like healthcare. The…
AI takes center stage at ORNL, where potential meets risk
In the early 1990s, the internet seemed poised to improve our lives by democratizing knowledge, publishing, and communication. While it did achieve many of these goals, it also introduced security risks ranging from malware to phishing. The online world of 2024 feels more like a war zone than a digital playground, “If you connect a…
New model sharpens antibody predictions, aiding faster vaccine and biologics development
Researchers have made significant strides in predicting a protein’s structure from its sequence using large language models. However, this method hasn’t been as effective for antibodies, primarily due to their hypervariability. This makes it challenging to identify treatments for SARS-CoV-2 and other infectious diseases. MIT researchers have developed a computational technique that more accurately predicts…
GLP-1 medications: A promising solution for not just diabetes
In the decades-long search for a “silver bullet” to tackle the U.S. obesity crisis, immense sums have been spent on diets, pills, and intensive workout programs. Now, researchers say GLP-1 — originally a treatment for type 2 diabetes — also addresses obesity, effectively solving two problems at once. But there may be additional benefits. A…
Study reveals blueprint for child-specific cancer immunotherapies
A study led by Professor Petter Brodin, a pediatrician and immunologist at the MRC Laboratory of Medical Sciences (LMS) and Imperial College London, analyzed 191 children aged 0 to 18, all diagnosed with various solid tumors at Stockholm’s Astrid Lindgren Children’s Hospital between 2018 and 2024. Researchers examined tumor samples to identify genetic mutations and…
R&D 100 winner of the day: MAVERICK, first turn-key device to use Raman spectroscopy for bioprocess control
MAVERICK is a platform designed specifically for biologists, using Raman spectroscopy to streamline bioprocess development and optimization. It offers out-of-the-box capabilities for real-time monitoring of variables like glucose, lactate, and biomass, all through an intuitive touchscreen interface. This platform supports automation, remote access, and compliance with cGMP standards for pharmaceutical industry applications. While Raman spectroscopy…
Study identifies 13 genes that increase osteoarthritis risk
Researchers at the UNC Thurston Arthritis Research Center have pinpointed 13 “high probability risk genes” that directly contribute to osteoarthritis, a condition affecting over 32 million people in the U.S. The findings, published in Cell Genomics, mark a significant step toward developing targeted therapies to prevent disease progression. The challenge of osteoarthritis Osteoarthritis occurs when…
Stimulating fat cells with GIP receptors shows promise for obesity treatment
A study led by UT Southwestern Medical Center researchers has shown that increasing glucose-dependent insulinotropic polypeptide receptor (GIPR) activity in fat cells leads to significant weight loss in obese mice. Published in Cell Metabolism, the research highlights GIPR’s potential as a therapeutic target for obesity and related metabolic diseases. “Our study brings GIPR in fat…
R&D 100 winner of the day: Thermo Scientific Orbitrap Astral mass spectrometer
Thermo Fisher Scientific’s Orbitrap Astral mass spectrometer transforms proteomics by enabling rapid and detailed analysis of biological samples. It can identify over 8,000 protein groups from a human cell line digest in just eight minutes, significantly enhancing experimental scale and statistical power. The instrument integrates three advanced technologies: a high-resolution quadrupole mass filter, the Thermo…
New AI model enhances antibody structure prediction for drug development
MIT researchers have developed AbMap, a computational model that predicts antibody structures with improved accuracy. This could accelerate the development of treatments for infectious diseases like SARS-CoV-2. Unlike existing AI models, AbMap focuses on antibodies’ hypervariable regions — highly diverse segments critical for binding pathogens — and overcomes limitations in previous protein modeling approaches. Using…
R&D Market Pulse: Honda eyes merger with Nissan, Xerox reacquires Lexmark and Microsoft’s Copilot sparks controversy
The R&D World Index (RDWI) for the week ending December 27, 2024, closed at 3,890.59, rising 1.77% (or 67.68 basis points). Automotive stocks, in particular, drove the uptick, with Honda surging by 20.39% after announcing a merger plan with Nissan. Meanwhile, tech giants showed mixed results, as IBM slid slightly (-0.26%) and Microsoft dropped -1.38%.…
Space Station research returns, advancing cancer and neurodegenerative therapies
Dozens of ambitious scientific investigations — including projects aiming to improve cancer detection, advance treatments for neurodegenerative diseases, and enhance respiratory therapy — have safely returned to Earth from the International Space Station (ISS). The nearly 50 experiments, sponsored by the ISS National Laboratory, were transported back on SpaceX’s 31st Commercial Resupply Services (CRS) mission…
25 techbio leaders that shaped the AI-biology convergence in 2024
While the term “biotechnology” was coined in 1919, “techbio” dates back roughly a century after that. Around 2019, the VC firm Artis Ventures set up a venture capital fund named Artis techbio with the aim of uniting software, computational biology, and drug development into a cohesive framework. The ambition behind this idea has sometimes surpassed…
This week in R&D: Vast Space unveils Haven 2 station plans; White House backs $32B AI R&D boost
The R&D World Index (RDWI) for the week ending October 25, 2024, closed at 3962.81 for the 25 companies in the RDWI. The Index was down -1.49% (or -60.14 basis points). Seven RDWI members gained value last week from 0.27% (Toyota) to 5.88% (General Motors). Eighteen RDWI members lost value the previous week from -0.27%…
How much does the pharma industry spend on R&D anyway? Probably more than you thought
For years, incomplete data and misconceptions have clouded the question of pharmaceutical how much it costs to bring therapies to market. The lack of clarity has led to debates over drug pricing, industry profits, and healthcare policies that are not always rooted in reality. For instance, a common belief persists that drug developers spend more…
This week in R&D: ULA launches second rocket, Microsoft sets up AI in Italy, and India and U.S. form R&D partnerships
The R&D World Index (RDWI) for the week ending October 4, 2024, closed at 4.005.40 for the 25 companies in the RDWI. The Index was up 0.62% (or 24.71 basis points). Eight RDWI members gained value last week from 1.07% (Eli Lilly & Co.) to 6.71% (Alibaba). Seventeen RDWI members lost value the previous week…
This week in R&D: Slight increase in global economic growth expected in 2024, Korean chipmakers visit UAE, and AstraZeneca mapping immune cells with AI
The R&D World Index (RDWI) for the week ending September 27, 2024, closed at 3,980.69 for the 25 companies in the RDWI. The Index was down -0.66% (or -26.26 basis points). Thirteen RDWI members gained value last week from 0.03% (Sanofi SA) to 20.30% (Alibaba). Twelve RDWI members lost value the previous week from -0.21%…
This week in R&D: GM and Hyundai to partner on vehicle development, Moderna cuts $1.1B in R&D spending, and Fed interest rate decision
The R&D World Index (RDWI) for the week ending September 13, 2024, closed at 3,924.01 for the 25 companies in the RDWI. The Index was up 2.95% (or 112.59 basis points). Seventeen RDWI members gained value last week from 0.30% (Volkswagen AG) to 14.26% (Oracle). Eight RDWI members lost value the previous week from -0.85%…
This week in R&D: AMD puts R&D centers in Taiwan cities, Northvolt relocates battery operations to its Sweden R&D center
The R&D World Index (RDWI) for the week ending August 23, 2024, closed at 3,947.43 for the 25 companies in the RDWI. The Index was up 1.78% (or 68.94 basis points). Twenty-two RDWI members gained value last week from 0.11% (Meta Platforms) to 7.23% (Ford Motor). Three RDWI members lost value the previous week from…
From self-driving cars to an autonomous AI/ML analytical platform for drug discovery
What do frictionless parking experiences and life-saving drugs have in common? For data scientist June Guo, the answer lies in setting AI algorithms loose on vast troves of data. Before setting his sights on human biology, Guo worked at Metropolis Technologies, a company focused on transforming the parking experience through the use of advanced computer…
Top 30 R&D spending leaders of 2023: Big Tech firms spending hit new heights
In 2023, the world’s top companies invested hefty sums in R&D, with tech giants like Amazon, Alphabet, and Meta leading the pack. Amazon alone poured $85.622 billion into technology and infrastructure, which includes R&D. The Seattle-headquartered company’s spending reflects Amazon’s ambition to lead not just in e-commerce, but in a growing number of fields ranging…